美国预防COVID-19住院的SARS-CoV-2疫苗有效性评价中检测阴性对照与综合征阴性对照的比较
研究纳入2021年3月11日至8月31日在18个州21家医疗中心住院的5811名成人,比较检测阴性对照与综合征阴性对照的特征及mRNA疫苗有效性估计。两对照组在年龄、种族/民族、就业、既往住院、基础疾病和免疫抑制等方面存在差异,但各对照组疫苗有效性估计非常接近;作者认为这些发现支持使用检测阴性对照。
要点
- 两对照组在人口学和临床特征上存在差异,但疫苗有效性估计非常接近。
- 18-64岁免疫功能正常者中,综合征阴性对照疫苗有效性93%(95%CI:90-94),检测阴性对照91%(95%CI:88-93)。
- 作者认为这些发现支持使用检测阴性对照,并增强了对检测阴性设计研究所得COVID-19疫苗有效性估计的信心。
核心结论
- 尽管两对照组在人口学和临床特征上存在差异,使用任一对照组在各年龄组和免疫抑制状态下的疫苗有效性估计均相似。
- 这些发现支持使用检测阴性对照,并增强了对检测阴性设计研究所得COVID-19疫苗有效性估计的信心。
研究设计与样本
- 研究纳入2021年3月11日至8月31日在18个州21家医疗中心住院的成人,共5811人。
- 病例为有症状的急性呼吸道感染且SARS-CoV-2检测阳性的住院患者。
- 检测阴性对照为有急性呼吸道感染但SARS-CoV-2检测阴性的患者,综合征阴性对照为无急性呼吸道感染且SARS-CoV-2检测阴性的患者。
- 采用卡方检验和Wilcoxon秩和检验比较基线特征,采用logistic回归比较病例与各对照组既往mRNA疫苗接种的调整比值比以计算疫苗有效性。
主要发现
- 共纳入5811名成人,其中病例2726例、检测阴性对照1696例、综合征阴性对照1389例。
- 两对照组在年龄、种族/民族、就业、既往住院、基础疾病和免疫抑制等特征上存在差异。
- 各对照组对应的疫苗有效性估计非常接近。
- 18-64岁免疫功能正常患者中,使用综合征阴性对照的疫苗有效性为93%(95%CI:90-94),使用检测阴性对照为91%(95%CI:88-93)。
关键数值与推荐
- 18-64岁免疫功能正常患者中,综合征阴性对照的疫苗有效性为93%(95%CI:90-94)。
- 18-64岁免疫功能正常患者中,检测阴性对照的疫苗有效性为91%(95%CI:88-93)。
临床怎么用
- 作者认为这些发现支持使用检测阴性对照,并增强了对检测阴性设计研究所得COVID-19疫苗有效性估计的信心。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Test-negative design (TND) studies have produced validated estimates of vaccine effectiveness (VE) for influenza vaccine studies. However, syndrome-negative controls have been proposed for differentiating bias and true estimates in VE evaluations for COVID-19. To understand the use of alternative control groups, we compared characteristics and VE estimates of syndrome-negative and test-negative VE controls. METHODS: Adults hospitalized at 21 medical centers in 18 states March 11-August 31, 2021 were eligible for analysis. Case patients had symptomatic acute respiratory infection (ARI) and tested positive for SARS-CoV-2. Control groups were test-negative patients with ARI but negative SARS-CoV-2 testing, and syndrome-negative controls were without ARI and negative SARS-CoV-2 testing. Chi square and Wilcoxon rank sum tests were used to detect differences in baseline characteristics. VE against COVID-19 hospitalization was calculated using logistic regression comparing adjusted odds of prior mRNA vaccination between cases hospitalized with COVID-19 and each control group. RESULTS: 5811 adults (2726 cases, 1696 test-negative controls, and 1389 syndrome-negative controls) were included. Control groups differed across characteristics including age, race/ethnicity, employment, previous hospitalizations, medical conditions, and immunosuppression. However, control-group-specific VE estimates were very similar. Among immunocompetent patients aged 18-64 years, VE was 93 % (95 % CI: 90-94) using syndrome-negative controls and 91 % (95 % CI: 88-93) using test-negative controls. CONCLUSIONS: Despite demographic and clinical differences between control groups, the use of either control group produced similar VE estimates across age groups and immunosuppression status. These findings support the use of test-negative controls and increase confidence in COVID-19 VE estimates produced by test-negative design studies.
引用
- Turbyfill C, Adams K, Tenforde MW, et al. Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States. Vaccine. 2022. PMID: 36374708. doi:10.1016/j.vaccine.2022.10.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。